WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
OverviewZen RatingPriceValueGrowthFinancialsMomentumSentimentForecast
DividendsDue Diligence
B
Diagnostics & Research is Zen Rated B and is the 36th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
CDNA
CAREDX INC
$2.59B$50.11$53.005.77%Buy27.26%-20.65%20.36%16.26%
SHC
SOTERA HEALTH CO
$5.39B$18.90$22.0016.40%Strong Buy55.10%27.76%54.56%10.98%
A
AGILENT TECHNOLOGIES INC
$43.37B$153.56$171.4411.64%Strong Buy175.35%14.35%34.64%18.88%
NEOG
NEOGEN CORP
$2.52B$11.56$14.0021.11%Strong Buy10.39%N/A-1.17%-0.73%
DGX
QUEST DIAGNOSTICS INC
$26.52B$240.30$243.861.48%Buy74.58%11.36%20.94%9.29%
ILMN
ILLUMINA INC
$32.26B$213.63$193.39-9.48%Hold135.95%9.56%42.96%18.34%
TMO
THERMO FISHER SCIENTIFIC INC
$228.17B$617.10$590.82-4.26%Buy115.07%17.72%24.21%11.27%
NEO
NEOGENOMICS INC
$2.30B$17.91$17.00-5.08%Strong Buy58.40%N/A10.24%5.95%
LH
LABCORP HOLDINGS INC
$26.98B$332.66$329.38-0.99%Strong Buy85.25%21.87%21.60%10.03%
WAT
WATERS CORP
$40.74B$414.63$419.441.16%Buy1818.28%66.82%13.87%8.52%
IQV
IQVIA HOLDINGS INC
$42.99B$261.19$247.80-5.13%Strong Buy105.19%26.11%48.23%9.96%
NTRA
NATERA INC
$46.41B$321.96$316.91-1.57%Strong Buy1816.02%N/A24.36%16.70%
IDXX
IDEXX LABORATORIES INC
$43.86B$556.69$681.2522.38%Buy47.73%10.29%104.40%48.90%
BDSX
BIODESIX INC
$277.97M$26.35$31.3318.93%Strong Buy314.96%N/A-119.27%-11.44%
CSTL
CASTLE BIOSCIENCES INC
$1.01B$33.03$41.7526.40%Strong Buy48.62%N/A2.12%1.78%
MTD
METTLER TOLEDO INTERNATIONAL INC
$28.15B$1,405.14$1.46k3.58%Buy104.34%9.29%10,075.58%35.20%
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$13.76B$288.24$270.13-6.28%Strong Buy81.92%N/A24.42%9.21%
RVTY
REVVITY INC
$14.36B$128.67$109.50-14.90%Buy93.88%46.81%11.36%6.82%
XGN
EXAGEN INC
$177.81M$7.34$9.5730.40%Strong Buy78.87%N/A8.01%1.88%
DHR
DANAHER CORP
$150.13B$213.56$213.920.17%Strong Buy146.98%22.17%15.65%8.91%
MEDP
MEDPACE HOLDINGS INC
$16.58B$593.99$580.88-2.21%Hold86.50%7.77%151.78%32.01%
ICLR
ICON PLC
$12.73B$164.99$179.929.05%Buy123.09%46.77%12.35%7.06%
OPK
OPKO HEALTH INC
$1.10B$1.47N/AN/AHold11.38%N/AN/AN/A
BLLN
BILLIONTOONE INC
$4.28B$90.67$118.7530.97%Strong Buy422.05%24.46%N/AN/A
PRPO
PRECIPIO INC
$49.57M$27.69N/AN/AN/AN/AN/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$8.72B$139.00$101.63-26.89%Strong Buy813.96%N/A24.25%16.08%
RDNT
RADNET INC
$5.97B$75.82$86.5014.09%Strong Buy211.62%N/A8.15%2.11%
STIM
NEURONETICS INC
$216.40M$2.84$4.5058.45%Strong Buy27.93%N/A-130.62%-17.73%
QGEN
QIAGEN NV
$8.95B$43.29$43.11-0.41%Buy94.83%15.10%19.30%11.00%
QUCY
QUANTUM CYBER NV
$131.99M$1.57N/AN/AN/AN/A245.88%N/AN/AN/A
GH
GUARDANT HEALTH INC
$21.34B$159.02$187.5317.93%Strong Buy1928.83%N/A-239.24%27.88%
ADVB
ADVANCED BIOMED INC
$13.06M$9.45N/AN/AN/AN/AN/AN/AN/AN/A
GRAL
GRAIL INC
$3.55B$79.37$65.00-18.11%Buy520.60%N/A-19.32%-17.28%
BIAF
BIOAFFINITY TECHNOLOGIES INC
$2.46M$4.56N/AN/AN/AN/AN/AN/A-118.40%-58.57%
ACRS
ACLARIS THERAPEUTICS INC
$890.55M$6.05$11.8095.04%Strong Buy5-11.17%N/A-106.29%-73.69%
MDXH
MDXHEALTH SA
$3.70M$0.72$2.17200.97%Strong Buy38.03%N/AN/AN/A
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$128.28M$3.92$8.50116.84%Strong Buy2163.33%N/AN/A-70.29%
MYGN
MYRIAD GENETICS INC
$307.99M$3.22$3.8820.34%Hold43.61%N/A18.30%8.70%
FLGT
FULGENT GENETICS INC
$532.97M$19.37$19.00-1.91%Hold19.62%N/A-4.48%-4.12%
SERA
SERA PROGNOSTICS INC
$83.63M$2.12$6.00183.02%Buy1364.56%N/A-38.63%-26.44%
DRIO
DARIOHEALTH CORP
$72.22M$7.37$10.0035.69%Strong Buy321.51%N/A16.51%9.42%
BNR
BURNING ROCK BIOTECH LTD
$99.41M$9.45N/AN/AN/AN/AN/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$5.92M$0.43$12.002,664.98%Buy3115.52%N/A-25.97%100.63%
TRIB
TRINITY BIOTECH PLC
$6.16M$9.87N/AN/AN/AN/AN/AN/AN/A-5.93%
NDRA
ENDRA LIFE SCIENCES INC
$7.51M$5.01$25.00399.50%Buy1N/AN/A-73.71%-58.56%
ISPC
ISPECIMEN INC
$3.88M$1.54N/AN/AN/AN/AN/AN/AN/AN/A
PSNL
PERSONALIS INC
$1.79B$16.78$15.17-9.61%Buy430.86%N/A-26.87%-20.24%
FRNM
FREENOME INC
$1.58B$14.79$18.0021.70%Strong Buy5N/AN/AN/AN/A
MBAI
CHECK-CAP LTD
$6.63M$6.61N/AN/AN/AN/AN/AN/AN/AN/A
XWEL
XWELL INC
$7.84M$0.91N/AN/AN/AN/AN/AN/AN/AN/A
1

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)


Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 51, which is 22 points higher than the diagnostic & research industry average of 29.

CDNA passed 17 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 261.81% over the past year, overperforming other diagnostic & research stocks by 239 percentage points.

Caredx has an average 1 year price target of $53.00, an upside of 5.77% from Caredx's current stock price of $50.11.

Caredx stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Caredx, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 40, which is 11 points higher than the diagnostic & research industry average of 29.

SHC passed 14 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 16.96% over the past year, underperforming other diagnostic & research stocks by -6 percentage points.

Sotera Health Co has an average 1 year price target of $22.00, an upside of 16.4% from Sotera Health Co's current stock price of $18.90.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 80% have issued a Strong Buy rating, 0% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: C.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 51, which is 22 points higher than the diagnostic & research industry average of 29.

A passed 19 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock return 22.64% over the past year.

Agilent Technologies has an average 1 year price target of $171.44, an upside of 11.64% from Agilent Technologies's current stock price of $153.56.

Agilent Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 17 analysts covering Agilent Technologies, 64.71% have issued a Strong Buy rating, 23.53% have issued a Buy, 11.76% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 5.29%, which is 4 percentage points higher than the diagnostic & research industry average of 1.34%.

Qiagen Nv's dividend payout ratio of 243.6% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.38%, which is the same as the diagnostic & research industry average of 1.34%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 34.8% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.87%, which is the same as the diagnostic & research industry average of 1.34%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.7% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.54% in the last day, and down -1.12% over the last week. Volitionrx was the among the top losers in the diagnostics & research industry, dropping -3.34% yesterday.

VolitionRX shares are trading lower after the company filed a prospectus for an offering of 10 million shares.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -7.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -31 percentage points.

2. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 30 points higher than the diagnostic & research industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -7.23% in the past year. It has underperformed other stocks in the diagnostic & research industry by -30 percentage points.

3. Thermo Fisher Scientific (NYSE:TMO)


Thermo Fisher Scientific (NYSE:TMO) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has gained 26.58% in the past year. It has overperformed other stocks in the diagnostic & research industry by 4 percentage points.

Are diagnostic & research stocks a good buy now?

53.66% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 2.82% over the next year.

5.13% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 17.95% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 10.26% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 14.49x.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.